- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04570293
5% Lidocaine-medicated Plaster for the Treatment of Trigeminal Neuralgia
The PATCH Trial: Effectiveness and Safety of 5% Lidocaine-medicated Plaster for the Treatment of Trigeminal Neuralgia
Trigeminal neuralgia (TN) is characterized by sudden, severe, usually unilateral, transient, stinging, recurrent electrocute-like shock in one or more divisions of the trigeminal nerve, lasting from a few seconds to less than 2 minutes.Simple daily-life activities, such as washing the face, brushing the teeth, eating, and talking, or the slight touch of trigger points may trigger the attack of pain of TN, resulting in a decline in the patient's quality of life (QoL). Trigger zones predominantly locate in the perioral and nasal region. Paroxysmal pain is associated with triggers in virtually all patients with TN. TN may be caused by abnormality of the trigger zone and the blockade of Na+ channel of trigger zone may be a novel and effective treatment methods for TN. Currently, most patients with TN may not achieve adequate pain relief with a single therapeutic agent. Multiple analgesics targeting different mechanisms of the pain pathway are often used.5% lidocaine medicated plaster (LMP) is a white hydrogel plaster containing adhesive material. LMP was approved for post-herpetic neuralgia (PHN) treatment by the United States Food and Drug Administration (FDA) in 1999. Tamburin et al reported that 2 patients with primary TN who stopped oral drugs because of side effects or refused surgical procedures. Both patients were instructed to wear LMP over the affected area and LMP resulted in reduction of pain intensity and the number of pain paroxysms without side effects. However, due to limitations of these open-label design studies, the observed reductions in pain intensity may have been due to treatment effect, placebo effect, changes in underlying disease state, or a combination of these factors. Therefore, randomized controlled trials will be need to be performed to draw about the efficacy of the LMP in TN.
The PATCH trial is a prospective, double-blinded, vehicle-controlled, parallel-group, multicenter, enriched enrolment with randomized withdrawal (EERW) trial aimed at estimating the efficacy and safety of LMP in patients with TN. After providing informed consent and completing a baseline evaluation, patients will participate in an initial open-label treatment period of LMP (active patches). This openly titrated process is close to clinical practice and can provide data on the proportion of responders and non-responders, the optimal dose of the analgesic drug, and the proportion of withdrawal due to adverse effects. A responder at the end of the open-label treatment phase will be included in the subsequently double-blind treatment phase.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Fang Luo, M.D.
- Phone Number: 86 13611326978
- Email: 13611326978@163.com
Study Contact Backup
- Name: Chunmei Zhao, M.D.
- Phone Number: 86 15510286930
- Email: zhaochunmei1206@163.com
Study Locations
-
-
-
Beijing, China
- Beijing China-Janpan Friendship Hospital
-
Beijing, China
- Sanbo Brain Hospital, Capital Medical University
-
Jilin, China
- Jilin Province People's Hospital
-
Shanxi, China
- Linfen People's Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Beijing Tiantan Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Occurrence of episodes of intense facial paroxysmal pain in the distribution(s) of one or more divisions of the trigeminal nerve, triggered by innocuous stimuli;
- Average daily pain intensity ≥ 4 by a brief pain inventory-short form (BPI-SF) Item 5 score (0-10 rating scale of average pain) in the preceding 24-hour period;
- Concomitant analgesic regimens that include 14 days of stable doses with systemic analgesics rather than topical agents for relief of PHN will be permitted
- Normal neurologic examination;
- Normal neuroimaging analysis.
Exclusion Criteria:
- Atypical pain location (eg, no specific trigger points) or trigger zones in the mouth;
- Proposed surgical intervention due to preference of the patient;
- Any condition known to interfere with the correct execution of the sensory tests (eg, peripheral or central neurological dysfunction or cognitive impairments);
- Presence of any other acute or chronic pain disorder with the need of systemic analgesic medication for more than 10 days in the last 3 months;
- Inability to discontinue the use of another lidocaine-containing products or a class I anti-arrhythmic drug during the study period;
- History of hypersensitivity to an amide-type local anesthetic agent, or other contents of the lidocaine or vehicle patch;
- History of surgical intervention or neurological ablation to treatment TN;
- Participation in another clinical trial within 30 days of the study;
- Any patient who was judged to be unreliable or unable to understand the protocol procedures;
- Any abnormality of the skin or of vascular origin at application site;
- Pregnancy or breastfeeding;.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: The LMP group
The LMP group will receive lidocaine patches (active patches) measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w).
|
The 5% lidocaine medicated plaster is measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w) For each patient, the painful area and the trigger point will be chosen for treatment.
The investigator will instruct the patient to replace the patch every 12 hours.
The patches could be applied during the night (application in the evening and removal in the morning), or during the day.
Patients will be told to apply up to three patches at one time.
|
Placebo Comparator: The control group
The control group will receive vehicle patches that are identical to the active patch, except for the absence of lidocaine, without any optical differences.
|
Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment.
The investigator will instruct the patient to replace the patch every 12 hours.
The patches could be applied during the night (application in the evening and removal in the morning), or during the day.
Patients will be told to apply up to three patches at one time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the number of treatment failures on LMP vs. number of treatment failures on vehicle patches throughout the double-blind treatment phase
Time Frame: Through study completion, an average of 7 weeks.
|
Patients will be defined as treatment failure at the end of the double-blind treatment phase or premature discontinuation if one of the following situations occurs:
|
Through study completion, an average of 7 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to loss of therapeutic response (LTR)
Time Frame: During the double-blind phase after randomization, an average of 7weeks.
|
LTR will be defined as number of days to treatment failure in the double-blind phase after randomization.
|
During the double-blind phase after randomization, an average of 7weeks.
|
Proportion of responders and non-responders
Time Frame: Through the open-label period, an average of 3 weeks.
|
A responder at the end of the open-label treatment phase will be defined as follows:
|
Through the open-label period, an average of 3 weeks.
|
the proportion of the patients who report pain relief of 50% or greater
Time Frame: At 3 weeks, 7 weeks
|
The pain relief will be assessed by Item 8 on the BPI-SF.
Patients will be asked to circle the percentage value from 0% (no relief) to 100% (complete relief) that shows how much pain relief they have achieved during the prior 24 hours at end of open-label phase, and end of double-blind phase or premature discontinuation
|
At 3 weeks, 7 weeks
|
The pain intensity
Time Frame: Through study completion, an average of 7 weeks.
|
Patients will be asked to circle the number on an 11-point Likert scale of 0 (no pain) to 10 (worst pain imaginable) that describe their worst pain (worst pain), their least pain (least pain) and their pain on average (average pain) in the previous 24 hours and how much pain they are experiencing at the time of the evaluation (pain right now).
|
Through study completion, an average of 7 weeks.
|
The number of paroxysms
Time Frame: Through study completion, an average of 7 weeks.
|
The number of paroxysms experienced in the past 4 days weekly
|
Through study completion, an average of 7 weeks.
|
The severity of paroxysms
Time Frame: Through study completion, an average of 7 weeks.
|
The severity of paroxysms experienced in the past 4 days weekly
|
Through study completion, an average of 7 weeks.
|
Quality of life (QoL)
Time Frame: Through study completion, an average of 7 weeks.
|
Pain interference with the QOL will be assessed by Items 9A-G on the BPI-SF weekly.
On these items, patients will be also asked to circle the number on an 11-point Likert scale of 0 (does not interfere) to 10 (completely interferes) that describes the extent to which pain have interfered with their activities of daily living during the prior 24 hours.
|
Through study completion, an average of 7 weeks.
|
Pittsburgh Sleep Quality Index (PSQI) at baseline, at end of open-label phase, and end of double-blind phase or premature discontinuation
Time Frame: At baseline, 3 weeks, 7weeks
|
Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.
The sum of scores for these seven components yields one global score.
The total scores are 21.
The higher the scores mean the worse the sleep.
|
At baseline, 3 weeks, 7weeks
|
Short form 36 health survey questionnaire (SF-36) at baseline, end of open-label phase, and end of double-blind phase or premature discontinuation
Time Frame: At baseline, 3 weeks, 7weeks
|
It measures health on eight multi-item dimensions, covering functional status, wellbeing, and overall evaluation of health.
|
At baseline, 3 weeks, 7weeks
|
The cost of treatment
Time Frame: Through study completion, an average of 7 weeks.
|
The total cost of all medications for TN and the cost of LMP
|
Through study completion, an average of 7 weeks.
|
Patient Global Impression of Change (PGIC) at end of open-label phase, and end of double-blind phase or premature discontinuation
Time Frame: At 3 weeks, 7 weeks
|
A 7-point Likert scale, where 1 = very much improved to 7 = very much worse with a value of 4 representing no change
|
At 3 weeks, 7 weeks
|
Study blindness
Time Frame: Through study completion, an average of 7 weeks.
|
Both the clinician and patient can guess whether the drug used during double-blind phase is LMP or vehicle patches.
|
Through study completion, an average of 7 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fang Luo, Beijing Tiantan Hospital
Publications and helpful links
General Publications
- Di Stefano G, Maarbjerg S, Nurmikko T, Truini A, Cruccu G. Triggering trigeminal neuralgia. Cephalalgia. 2018 May;38(6):1049-1056. doi: 10.1177/0333102417721677. Epub 2017 Jul 14.
- Liu M, Zhong J. Mechanism underlying cranial nerve rhizopathy. Med Hypotheses. 2020 Sep;142:109801. doi: 10.1016/j.mehy.2020.109801. Epub 2020 May 6.
- Cheville AL, Sloan JA, Northfelt DW, Jillella AP, Wong GY, Bearden Iii JD, Liu H, Schaefer PL, Marchello BT, Christensen BJ, Loprinzi CL. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Support Care Cancer. 2009 Apr;17(4):451-60. doi: 10.1007/s00520-008-0542-x. Epub 2009 Jan 13.
- Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003 Feb;43(2):111-7. doi: 10.1177/0091270002239817.
- Tamburin S, Schweiger V, Magrinelli F, Brugnoli MP, Zanette G, Polati E. Effect of 5% lidocaine medicated plaster on pain intensity and paroxysms in classical trigeminal neuralgia. Ann Pharmacother. 2014 Nov;48(11):1521-4. doi: 10.1177/1060028014544166. Epub 2014 Jul 28.
- Zhao C, Shrestha N, Liu H, Shen Y, Meng L, Fan B, Luo F. The PATCH trial: efficacy and safety of 5% lidocaine-medicated plaster for the treatment of patients with trigeminal neuralgia: a study protocol for a multicentric, double-blind, enriched enrolment randomised withdrawal, vehicle-controlled study. BMJ Open. 2021 Aug 2;11(8):e045493. doi: 10.1136/bmjopen-2020-045493.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Peripheral Nervous System Diseases
- Cranial Nerve Diseases
- Facial Nerve Diseases
- Trigeminal Nerve Diseases
- Facial Neuralgia
- Neuralgia
- Trigeminal Neuralgia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- KY 2020-102-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trigeminal Neuralgia
-
Klinikum Klagenfurt am WörtherseeUniversity of KlagenfurtCompletedGlossopharyngeal Neuralgia | Trigeminal Neuralgia, Idiopathic | Postherpetic; Neuralgia, Trigeminal (Etiology) | Atypical Facial PainAustria
-
University of FloridaFacial Pain Research FoundationCompleted
-
Beijing Tiantan HospitalCompletedTrigeminal Neuralgia, SecondaryChina
-
BiogenCompletedTrigeminal Neuralgia (TN) | Other Neuropathic PainUnited States
-
Shifa Clinical Research CenterCompletedTrigeminal Neuralgia, Idiopathic
-
Ziekenhuis Oost-LimburgCompletedTrigeminal Neuralgia (TN)Belgium
-
Vanderbilt University Medical CenterCompletedTrigeminal NeuralgiaUnited States
-
Seoul National UniversityRecruitingFacial Pain | Cluster Headache | Trigeminal Neuralgia | Postherpetic NeuralgiaKorea, Republic of
-
Beijing Tiantan HospitalBeijing Friendship Hospital; Beijing Ditan HospitalCompletedIdiopathic Trigeminal NeuralgiaChina
-
Danish Headache CenterRecruitingTrigeminal NeuralgiaDenmark
Clinical Trials on 5% lidocaine medicated plaster
-
Scilex Pharmaceuticals, Inc.Completed
-
Grünenthal GmbHTerminatedPain | Chronic Pain | Postoperative Pain | Neuropathic PainFrance
-
Grünenthal GmbHCompletedPain | Chronic Pain | Postoperative Pain | Neuropathic PainAustria, Belgium, Brazil, Denmark, France, Italy, Spain, United Kingdom
-
Grünenthal GmbHCompleted
-
Danish Pain Research CenterGrünenthal Denmark ApSCompleted
-
Grünenthal GmbHCompletedPost Herpetic Neuralgia
-
Hubei Hospital of Traditional Chinese MedicineUnknown
-
Fidia Farmaceutici s.p.a.CompletedInflammation | Trauma InjuryHungary, Germany, Italy
-
Medherant LtdCooperative Clinical Drug Research and Development AG (CCDRD AG)Completed
-
Fidia Farmaceutici s.p.a.RecruitingLow Back Pain, MechanicalItaly